Results 271 to 280 of about 436,330 (367)

Hypoxia regulates Th17/Treg balance by altering chromatin accessibility and gene expression

The FEBS Journal, EarlyView.
T‐cell differentiation into Th17 or iTreg cells is key to inflammation control. Integrated RNA‐seq and ATAC‐seq analyses reveal that hypoxia induces more extensive gene expression changes in iTreg cells. Elevated levels of Hif1a and Stat3, along with increased accessibility to key transcription factor motifs, may predispose these cells toward ...
Mariana Cázares‐Olivera, Shiyang Song, Sofia Ylinen, Talha Qureshi, Bin Li, Zhi Chen   +5 more
wiley   +1 more source

Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series. [PDF]

Int J Womens Dermatol
Ogbutor C, Chen LC, Kalil LL, Kelley KJ, Craiglow BG, King B, Senna MM.   +6 more
europepmc   +1 more source

Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata [PDF]

Melissa Piliang, Jennifer Soung, Brett King, Jerry Shapiro, Lidia Rudnicka, Paul Farrant, Nina Magnolo, Bianca Maria Piraccini, Xin Luo, Robert Wołk, Deborah Woodworth, Gregor Schaefer, Alexandre Lejeune   +12 more
openalex   +1 more source

Extracellular vesicles released from melanoma cells constitutively expressing MHC class II promote immune evasion and cancer progression

The FEBS Journal, EarlyView.
Here, we report the role of extracellular vesicles (EVs) released from melanoma cells constitutively expressing MHC class II in the regulation of immune cell functions and melanoma metastasis. In particular, we observed an increased localization of HLA‐DRα, CAM receptors, PD‐L1, and STAT3 signaling proteins in the EVs.
Francesca Costantini, Caterina Di Sano, Samuele Raccosta, Mauro Manno, Giovanna Barbieri   +4 more
wiley   +1 more source

Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility (JAKPPPOT) trial protocol. [PDF]

BMJ Open
Gleeson D, Chapman S, McAteer H, Qin A, Gregory J, Pizzato J, Powell K, Sagoo MK, Ye W, Naylor A, Moorhead L, Pink AE, Woolf R, Barker J, Galloway JB, Cro S, K Mahil S, Smith CH.   +17 more
europepmc   +1 more source

Safety and effectiveness of the combination of 5‐azacitidine and ruxolitinib in VEXAS syndrome: A single‐centre experience

British Journal of Haematology, EarlyView.
Gregorio Maria Bergonzi, Enrico Cozzo, Alessandro Tomelleri, Costanza Piccolo, Gianluca Scorpio, Carmelo Gurnari, Francesca Romano, Marco Matucci‐Cerinic, Lorenzo Dagna, Massimo Bernardi, Luca Vago, Fabio Ciceri, Corrado Campochiaro, Elisa Diral   +13 more
wiley   +1 more source

A systematic literature review of Janus kinase inhibitors for the treatment of systemic sclerosis. [PDF]

J Scleroderma Relat Disord
Sener S, Sener YZ, Batu ED, Sari A, Akdogan A.   +4 more
europepmc   +1 more source

Treatment of rheumatoid arthritis with janus kinase inhibitors [PDF]

Pernille Holme Thorhauge, Lars Løkke Ottesen, Niels Lomborg   +2 more
openalex   +1 more source

Janus kinase inhibitors for alopecia areata: a review of clinical data. [PDF]

Front Immunol
Sun Y, Li Q, Zhang Y, Liu Y.
europepmc   +1 more source

Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta‐Analysis

International Journal of Dermatology, EarlyView.
ABSTRACT Prurigo nodularis (PN) is a chronic, intensely pruritic skin disorder characterized by hyperkeratotic nodules and a debilitating itch–scratch cycle. Conventional therapies have limited efficacy and safety issues, while biologics have recently emerged as a promising alternative.
Andrea Lancz, Fanni Adél Meznerics, Renáta Árok, Anna Sára Lengyel, Bence Szabó, Péter Hegyi, Norbert Kiss, András Bánvölgyi   +7 more
wiley   +1 more source